[go: up one dir, main page]

PE20090365A1 - Imidazopirazinas como inhibidores de proteina quinasa - Google Patents

Imidazopirazinas como inhibidores de proteina quinasa

Info

Publication number
PE20090365A1
PE20090365A1 PE2008001001A PE2008001001A PE20090365A1 PE 20090365 A1 PE20090365 A1 PE 20090365A1 PE 2008001001 A PE2008001001 A PE 2008001001A PE 2008001001 A PE2008001001 A PE 2008001001A PE 20090365 A1 PE20090365 A1 PE 20090365A1
Authority
PE
Peru
Prior art keywords
cr7r8
imidazopyrazines
nr5r6
ethyl
protein kinase
Prior art date
Application number
PE2008001001A
Other languages
English (en)
Inventor
David B Belanger
Angela D Kerekes
Zhaoyang Meng
Jayram R Tagat
Sara J Esposite
Yushi Xiao
Bheemashankar K Kulkarni
Yonglian Zhang
Patrick J Curran
Ronald J Doll
Tao Yu
Amit K Mandal
M Arshad Siddiqui
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40002934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090365(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090365A1 publication Critical patent/PE20090365A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE IMIDAZOPIRAZINAS DE FORMULA I, EN EL QUE R ES H, CN, -NR5R6, -N(R5)C(O)R6, ENTRE OTROS; R1 ES H, FLUOR, FENILO, TETRAHIDROISOQUINOLILO, ENTRE OTROS; R2 ES H, 2-FENETILO, 1,2,4-TIADIAZOLILO, BENZOFURAZANILO, ENTRE OTROS; R3 ES HETEROCICLIL-(CR7R8)n-X, HETEROCICLENIL-(CR7R8)n-X, HETEROARIL-(CR7R8)n-X O ARIL-(CR7R8)n-X; n ES DE 1 A 6; X ES -NR5R6, -OR5, SO2R5, ENTRE OTROS; R7 Y R8 SON H, ETILO, n-PROPILO, NAFTILO, CICLOHEXILMETILO, ENTRE OTROS; R5 ES ISOPROPILO, ETIL-SH, PIPERIDINILMETILO, ENTRE OTROS; R6 ES PIRROLIDINONA, 2-PIRIDINILMETILO, 2-NAFTALENMETOXI, FENOXICARBONILO, ENTRE OTROS. SON SELECCIONADOS II, III, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA CON UN SEGUNDO COMPONENTE ADICIONAL, TAL COMO CITARABINA, DOCETAXEL, TESTOLACTONA, RITUXIMAB, ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE PROTEINQUINASA MEDIANTE LA INHIBICION DE UNA AURORA QUINASA, POR LO QUE SON DE UTILIDAD EN PROCESOS DE HIPERPROLIFERACION CELULAR Y/O CANCER
PE2008001001A 2007-06-14 2008-06-11 Imidazopirazinas como inhibidores de proteina quinasa PE20090365A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94399907P 2007-06-14 2007-06-14
US98793207P 2007-11-14 2007-11-14

Publications (1)

Publication Number Publication Date
PE20090365A1 true PE20090365A1 (es) 2009-04-04

Family

ID=40002934

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001001A PE20090365A1 (es) 2007-06-14 2008-06-11 Imidazopirazinas como inhibidores de proteina quinasa

Country Status (10)

Country Link
EP (1) EP2170892A2 (es)
JP (1) JP2010529195A (es)
CN (1) CN101772500A (es)
AR (1) AR066958A1 (es)
CA (1) CA2690557A1 (es)
CL (1) CL2008001745A1 (es)
MX (1) MX2009013729A (es)
PE (1) PE20090365A1 (es)
TW (1) TW200911811A (es)
WO (1) WO2008156614A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102428087B (zh) 2009-04-16 2015-06-17 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的咪唑并吡嗪类化合物
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
ES2651296T3 (es) 2009-10-30 2018-01-25 Janssen Pharmaceutica, N.V. Derivados de imidazo[1,2-b]piridacina y su uso como inhibidores de PDE10
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US9199999B2 (en) * 2010-06-01 2015-12-01 Bayer Intellectual Property Gmbh Substituted imidazopyrazines
WO2012052954A1 (en) * 2010-10-20 2012-04-26 Universite Bordeaux Segalen Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
CA2821834A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
JP2014521595A (ja) 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスＢｃｌ阻害剤として有用な置換スルホンアミド
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
JP6174695B2 (ja) 2012-07-09 2017-08-02 ヤンセン ファーマシューティカ エヌ．ベー． ホスホジエステラーゼ１０酵素の阻害剤
PL3466955T3 (pl) 2014-01-13 2021-06-28 Aurigene Discovery Technologies Limited Sposób otrzymywania pochodnych oksazolo[4,5-B]pirydyny i tiazolo[4,5-B]pirydyny jako inhibitorów IRAK4 w leczeniu raka
EP3626713B1 (en) 2014-02-13 2021-09-29 Incyte Corporation Cyclopropylamines for use as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
SI3334709T1 (sl) 2015-08-12 2025-03-31 Incyte Holdings Corporation Soli zaviralca lsd1
MA44725A (fr) 2016-04-22 2019-02-27 Incyte Corp Formulations d'un inhibiteur de lsd1
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
IL269536B (en) * 2017-03-31 2022-07-01 Aurigene Discovery Tech Ltd Compounds and compositions for treating hematological disorders
CN107954977A (zh) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 雷替曲塞中间体的合成方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
EP4143190A1 (en) * 2020-04-29 2023-03-08 F. Hoffmann-La Roche AG Antibacterial 8-phenylamino-3-(pyrazol-4-yl)imidazo[1,2-a]pyrazine derivatives
CN116113406B (zh) * 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
EP4319750A4 (en) 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2023169438A1 (zh) * 2022-03-07 2023-09-14 上海凌达生物医药有限公司 一类含氮杂环类细胞周期抑制剂化合物、制备方法和用途
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE377600T1 (de) * 2002-09-23 2007-11-15 Schering Corp Imidazopyrazine als cdk-inhibitoren
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
WO2006053121A2 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
TW200804386A (en) * 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors

Also Published As

Publication number Publication date
CN101772500A (zh) 2010-07-07
WO2008156614A3 (en) 2009-02-12
JP2010529195A (ja) 2010-08-26
WO2008156614A2 (en) 2008-12-24
CL2008001745A1 (es) 2008-12-05
EP2170892A2 (en) 2010-04-07
MX2009013729A (es) 2010-01-25
CA2690557A1 (en) 2008-12-24
TW200911811A (en) 2009-03-16
AR066958A1 (es) 2009-09-23

Similar Documents

Publication Publication Date Title
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
PE20080928A1 (es) Derivados de anilinopiperazina como inhibidores de proteina quinasa
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
PE20071061A1 (es) Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf)
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
BRPI0915084B8 (pt) composto, e, composição farmacêutica
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
GT201100181A (es) "inhibidores de proteina cinasa"
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
MX2007016324A (es) Inhibidores hcv.
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
EA200800240A1 (ru) Производные тиазола в качестве активатора амфк
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
EA200870164A1 (ru) Лечение вирусного гепатита

Legal Events

Date Code Title Description
FC Refusal